Abeona Therapeutics ABEO: ZEVASKYN Momentum, ABO-701's PSMA Pivot, and a Growing QTC Network

Ticker: ABEO — analysis of Abeona Therapeutics' First Quarter 2026 results. Key datapoints include EPS considerations, EPS consensus, and a view on revenue forecast where disclosed.

May 13, 2026

Executive Snapshot

ZEVASKYN uptake progresses with three patients treated in Q1 2026; one treatment to date in Q2; one biopsy currently in manufacturing; six additional patients expected to be biopsied in Q2, three of whom have biopsies scheduled.
QTC network expands to six sites, activated at New York-Presbyterian / Columbia University Irving Medical Center in New York and Children’s Hospital of Philadelphia (CHOP).
Pipeline focus centers on ABO-701, a radically novel engineered T-cell therapy targeting PSMA, built on the SIR‑T platform to address limitations of CAR and TCR approaches.
Financial position shows $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026.
The press release does not include a revenue forecast or an explicit EPS figure, nor an earnings surprise or EPS consensus target for the quarter.

Management Commentary

“We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter,” said Vish Seshadri, PhD, President and CEO of Abeona Therapeutics. “We’re encouraged by the onboarding acceleration of QTCs so they can begin to treat patients with ZEVASKYN.”

Pipeline Update: ABO-701 and the SIR-T Advantage

Building on its end-to-end engineered cell therapy capabilities, Abeona will focus development on ABO-701, a PSMA-targeted engineered T-cell therapy. ABO-701 carries a Synthetic Immune Receptor (SIR-T) designed to overcome the limitations of current CAR and TCR approaches. The SIR-T platform was developed by Dr. Preet M. Chaudhary. This marks a strategic pivot toward targeting PSMA in advanced prostate cancer—a disease with substantial mortality and limited durable options despite multiple approved therapies.

QTC Network and Patient Access

The QTC network expansion to six sites includes activation of New York-Presbyterian / Columbia University Irving Medical Center and CHOP, aimed at increasing patient access to ZEVASKYN across major U.S. markets. Management notes published coverage policies now cover about 95% of commercially insured U.S. lives, a meaningful lever if product uptake scales post-approval and manufacturing aligns with demand.

SID2026 Data and Long-Term Safety

Data presented at SID2026 will address sustained wound healing and long-term safety after a one-time pz-cel application, including a 12-year case report and a 5-year Phase 3 data window. While this is not a near-term ADS (advertising statement) about imminent product revenue, it signals a potential durability story for the underlying platform that investors will watch for corroboration in future trials.

Financial Position and Near-Term Outlook

The company reports a cash position of $168.3M as of March 31, 2026. Notably, the release provides no revenue forecast, and it does not present current EPS data, nor does it offer an EPS consensus or any formal earnings surprise metric. This omission is typical for a clinical-stage biotech before meaningful sales traction, but it leaves the stock’s near-term narrative driven by pipeline milestones and manufacturing execution rather than a traditional quarterly earnings story.

Takeaways for the Sector

Abeona’s quarterly cadence underscores two enduring truths for engineered cell therapies: progress on the pipeline is inseparable from the ability to scale manufacturing and payer access. The six-site QTC network, paired with broad insurer coverage uptake, elevates the probability that ZEVASKYN, if clinically successful, can reach a sizable patient population. For sector peers, the lesson is plain: milestones around site expansion and durable safety data can matter as much as ad hoc efficacy signals when financing future bets or negotiating licensing deals.

Risks and Considerations

As with any early-stage biotechnology, execution risk remains high. ABO-701’s fate hinges on PSMA-targeted efficacy, safety signals, and manufacturing scalability. The reallocation away from ophthalmology programs may reduce near-term upside but could improve capital allocation discipline. The absence of a contemporary revenue forecast or concrete EPS data means investors will rely on trial readouts and pricing dynamics rather than quarterly earnings beats to gauge progress.

Bottom Line

Q1 2026 paints a constructive narrative: ZEVASKYN momentum is building, the QTC footprint is widening, and ABO-701’s PSMA focus marks a deliberate pivot toward a high-uncertainty but potentially high-reward segment. If the company can translate early clinical and access gains into durable manufacturing execution and clearer future revenue visibility, ABEO could see a broader re-pricing by peers who gauge the durability of its platform. In the meantime, investors will watch for any shifts in EPS trajectory, earnings surprises, or an updated revenue forecast as a barometer of impending scale.